Clinical Trials Logo

Filter by:
NCT ID: NCT00604643 No longer available - Clinical trials for Abdominal Aortic Aneurysms

Talent Aortic Cuff Stent Graft System Compassionate Use Registry

Start date: n/a
Phase:
Study type: Expanded Access

An evaluation of the TALENT Aortic Cuff in patients with existing AneuRx stent grafts who have experienced sub-optimal stent graft outcomes and are not deemed suitable candidates for treatment with an AneuRx Aortic Cuff.

NCT ID: NCT00589030 No longer available - Liver Cancer Clinical Trials

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: April 2007
Phase: N/A
Study type: Expanded Access

RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: To provide expanded access and study the side effects of yttrium Y 90 glass microspheres in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT00575549 No longer available - Clinical trials for Evaluation of Troponin I Levels

Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to prospectively analyze and compare conventional stress echocardiograms and real-time myocardial contrast stress echocardiograms; and to determine the effect of contrast agents used during real-time myocardial contrast stress echocardiograms on serum troponin I levels.

NCT ID: NCT00547235 No longer available - Infection Clinical Trials

Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection

Start date: September 2007
Phase: N/A
Study type: Expanded Access

RATIONALE: Collecting the T cells from a donor and transplanting them into a patient may be effective treatment for immunodeficiency syndrome and CMV infection. PURPOSE: This clinical trial is studying the emergency use of adoptive immunotherapy with CMV-specific T cells after donor bone marrow transplant of an infant with immunodeficiency syndrome and CMV infection.

NCT ID: NCT00508963 No longer available - Clinical trials for Leishmaniasis, Cutaneous

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Start date: n/a
Phase:
Study type: Expanded Access

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

NCT ID: NCT00423826 No longer available - Lymphoma Clinical Trials

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Start date: January 2007
Phase: N/A
Study type: Expanded Access

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil before the transplant may stop this from happening. PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant works in treating patients with hematologic cancer or other disease.

NCT ID: NCT00349739 No longer available - Clinical trials for Macular Degeneration

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

Start date: January 2003
Phase: N/A
Study type: Expanded Access

The purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.

NCT ID: NCT00302016 No longer available - Clinical trials for Chronic Myeloid Leukemia

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Start date: January 2006
Phase: Phase 3
Study type: Expanded Access

This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.

NCT ID: NCT00263978 No longer available - Liver Diseases Clinical Trials

Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

Start date: November 2005
Phase: N/A
Study type: Expanded Access

Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood and marrow transplantation. Treatment with currently available (Food and Drug Administration [FDA] approved) agents fails in most cases. Recently conducted clinical studies indicate that patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed not with a research intent, but rather to ensure that defibrotide is used by the blood and marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a safe, effective and ethical manner.

NCT ID: NCT00210665 No longer available - Sarcoma Clinical Trials

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to facilitate access to trabectedin for eligible previously treated patients with soft tissue sarcoma (STS), who cannot be expected to benefit from currently available therapeutic options but who may benefit from treatment with trabectedin. The safety profile of trabectedin will be evaluated to further assess the potential risks of trabectedin treatment.